Chemistry:Siplizumab
From HandWiki
Short description: Monoclonal antibody
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from rat) |
Target | CD2 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
![]() ![]() |
Siplizumab (MEDI-507) is an investigational monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and has been tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.[1][2][3][4][5]
References
- ↑ Podestà, Manuel A.; Binder, Christian; Sellberg, Felix; DeWolf, Susan; Shonts, Brittany; Ho, Siu-Hong; Obradovic, Aleksandar; Waffarn, Elizabeth et al. (January 2020). "Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro". American Journal of Transplantation 20 (1): 88–100. doi:10.1111/ajt.15533. PMID 31319439.
- ↑ Langley, Richard G.; Papp, Kim; Bissonnette, Robert; Toth, Darryl; Matheson, Robert; Hultquist, Micki; White, Barbara (July 2010). "Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies". International Journal of Dermatology 49 (7): 818–828. doi:10.1111/j.1365-4632.2010.04512.x. PMID 20618506.
- ↑ O'Mahony, Deirdre; Morris, John C.; Stetler-Stevenson, Maryalice; Matthews, Helen; Brown, Margaret R.; Fleisher, Thomas; Pittaluga, Stefania; Raffeld, Mark et al. (1 April 2009). "EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies". Clinical Cancer Research 15 (7): 2514–2522. doi:10.1158/1078-0432.CCR-08-1254. PMID 19293260.
- ↑ Adkins, Douglas; Ratanatharathorn, Voravit; Yang, Harry; White, Barbara (27 July 2009). "Safety Profile and Clinical Outcomes in a Phase I, Placebo-Controlled Study of Siplizumab in Acute Graft-Versus-Host Disease". Transplantation 88 (2): 198–202. doi:10.1097/TP.0b013e3181abfbf7. PMID 19623014.
- ↑ Cvetkovski, Filip; Razavi, Ronia; Sellberg, Felix; Berglund, Erik; Berglund, David (October 2023). "Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro". American Journal of Transplantation 23 (10): 1603–1611. doi:10.1016/j.ajt.2023.05.032. PMID 37270108.
![]() | Original source: https://en.wikipedia.org/wiki/Siplizumab.
Read more |